LT3880654T - 2-formil-3-hidroksifeniloksimetilo junginiai, galintys moduliuoti hemoglobiną - Google Patents
2-formil-3-hidroksifeniloksimetilo junginiai, galintys moduliuoti hemoglobinąInfo
- Publication number
- LT3880654T LT3880654T LTEPPCT/US2019/062054T LTUS2019062054T LT3880654T LT 3880654 T LT3880654 T LT 3880654T LT US2019062054 T LTUS2019062054 T LT US2019062054T LT 3880654 T LT3880654 T LT 3880654T
- Authority
- LT
- Lithuania
- Prior art keywords
- hydroxyphenyloxymethyl
- formyl
- compounds capable
- hemoglobin
- modulating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862769196P | 2018-11-19 | 2018-11-19 | |
| US201962821314P | 2019-03-20 | 2019-03-20 | |
| US201962848773P | 2019-05-16 | 2019-05-16 | |
| US201962883313P | 2019-08-06 | 2019-08-06 | |
| PCT/US2019/062054 WO2020106642A1 (en) | 2018-11-19 | 2019-11-18 | 2-formyl-3-hydroxyphenyloxymethyl compounds capable of modulating hemoglobin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3880654T true LT3880654T (lt) | 2022-02-25 |
Family
ID=68848454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEPPCT/US2019/062054T LT3880654T (lt) | 2018-11-19 | 2019-11-18 | 2-formil-3-hidroksifeniloksimetilo junginiai, galintys moduliuoti hemoglobiną |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US10683285B2 (lt) |
| EP (2) | EP4046988A1 (lt) |
| JP (1) | JP7509772B2 (lt) |
| KR (1) | KR20210093990A (lt) |
| CN (1) | CN113316568B (lt) |
| AU (1) | AU2019383960B2 (lt) |
| BR (1) | BR112021007044B1 (lt) |
| CA (1) | CA3120380A1 (lt) |
| CO (1) | CO2021007993A2 (lt) |
| CR (1) | CR20210335A (lt) |
| CY (1) | CY1125025T1 (lt) |
| DK (1) | DK3880654T3 (lt) |
| ES (1) | ES2908325T3 (lt) |
| HR (1) | HRP20220295T1 (lt) |
| HU (1) | HUE057323T2 (lt) |
| IL (1) | IL283128B1 (lt) |
| LT (1) | LT3880654T (lt) |
| MA (1) | MA54231B1 (lt) |
| MD (1) | MD3880654T2 (lt) |
| MX (1) | MX2021005887A (lt) |
| PL (1) | PL3880654T3 (lt) |
| PT (1) | PT3880654T (lt) |
| RS (1) | RS62970B1 (lt) |
| SA (1) | SA521422031B1 (lt) |
| SG (1) | SG11202104705RA (lt) |
| SI (1) | SI3880654T1 (lt) |
| TW (1) | TWI841630B (lt) |
| WO (1) | WO2020106642A1 (lt) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20160078A1 (es) | 2013-03-15 | 2016-03-02 | Global Blood Therapeutics Inc | Compuestos y sus usos para modular la hemoglobina |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| ES2890077T3 (es) | 2013-03-15 | 2022-01-17 | Global Blood Therapeutics Inc | Compuestos y usos de los mismos para la modulación de la hemoglobina |
| AU2014237340C1 (en) | 2013-03-15 | 2018-11-08 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| SG10201911662YA (en) | 2014-02-07 | 2020-02-27 | Global Blood Therapeutics Inc | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
| TW201731509A (zh) | 2015-12-04 | 2017-09-16 | 全球血液治療公司 | 針對２-羥基-６-（（２-（１-異丙基-１ｈ-吡唑-５-基）吡啶-３-基）甲氧基）-苯甲醛之劑量方案 |
| PL3483164T3 (pl) | 2017-03-20 | 2020-08-24 | Forma Therapeutics, Inc. | Kompozycje pirolopirolu jako aktywatory kinazy pirogronianowej (PKR) |
| BR112021005188A2 (pt) | 2018-09-19 | 2021-06-08 | Forma Therapeutics, Inc. | tratamento de anemia falciforme com um composto de ativação de piruvato cinase r |
| EP3852791B1 (en) | 2018-09-19 | 2024-07-03 | Novo Nordisk Health Care AG | Activating pyruvate kinase r |
| US11014884B2 (en) | 2018-10-01 | 2021-05-25 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin |
| LT3880654T (lt) * | 2018-11-19 | 2022-02-25 | Global Blood Therapeutics, Inc. | 2-formil-3-hidroksifeniloksimetilo junginiai, galintys moduliuoti hemoglobiną |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| AR126649A1 (es) * | 2021-05-14 | 2023-11-01 | Global Blood Therapeutics Inc | Formas sólidas de un modulador de hemoglobina |
| WO2022241286A1 (en) * | 2021-05-14 | 2022-11-17 | Global Blood Therapeutics, Inc. | Methods of making a modulator of hemoglobin |
| JP2024527819A (ja) | 2021-07-19 | 2024-07-26 | バイオアプリケーションズ インコーポレイテッド | 植物由来のｃｏｖｉｄ－１９変異組換えスパイクタンパク質発現ベクターおよび該発現ベクターを用いた組換えタンパク質 |
| IL312835A (en) * | 2021-12-10 | 2024-07-01 | Global Blood Therapeutics Inc | Methods for administering a hemoglobin modulator |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| DE3061269D1 (en) | 1979-06-29 | 1983-01-13 | Wellcome Found | Substituted phenol ethers, their preparation, intermediates therefor, pharmaceutical compositions containing them and the preparation thereof |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| EP0054924B1 (en) | 1980-12-18 | 1986-08-06 | The Wellcome Foundation Limited | Pharmaceutical compounds, their preparation and use |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| JPS63258463A (ja) | 1987-04-14 | 1988-10-25 | Kumiai Chem Ind Co Ltd | ２−フエノキシピリミジン誘導体及び除草剤 |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| EP0658559A1 (de) | 1993-12-14 | 1995-06-21 | Chemisch Pharmazeutische Forschungsgesellschaft m.b.H. | Thienothiazinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als 5-dipoxygenase und Cyclooxygenaseinhibitoren |
| CZ20012112A3 (cs) | 1998-12-14 | 2001-10-17 | F. Hoffmann-La Roche Ag | Derivát fenylglycinu |
| IL145164A0 (en) | 1999-03-31 | 2002-06-30 | Basf Ag | Substituted aniline compounds |
| RU2296758C2 (ru) | 2002-08-08 | 2007-04-10 | Смитклайн Бичем Корпорейшн | Производные тиофена |
| EP2179987B1 (en) | 2002-12-04 | 2013-02-13 | Virginia Commonwealth University | Use of heterocyclic carbaldehyde derivatives against sickle cell anemia |
| BRPI0411255A (pt) | 2003-06-12 | 2006-08-01 | Novo Nordisk As | composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto |
| US7847120B2 (en) | 2004-04-22 | 2010-12-07 | Virginia Commonwealth University Intellectual Property Foundation | Compositions of allosteric hemoglobin modifiers and methods of making the same |
| WO2007003962A2 (en) | 2005-06-30 | 2007-01-11 | Prosidion Limited | Gpcr agonists |
| CN100562514C (zh) | 2005-07-22 | 2009-11-25 | 中国科学院上海药物研究所 | 一类取代丙酰胺衍生物、其制备方法和用途 |
| TW200835687A (en) | 2006-11-30 | 2008-09-01 | R Tech Ueno Ltd | Thiazole derivatives and their use as VAP-1 inhibitor |
| US20090069288A1 (en) | 2007-07-16 | 2009-03-12 | Breinlinger Eric C | Novel therapeutic compounds |
| WO2009136889A1 (en) * | 2008-05-08 | 2009-11-12 | Nova Southeastern University | Specific inhibitors for vascular endothelial growth factor receptors |
| GB0811451D0 (en) | 2008-06-20 | 2008-07-30 | Syngenta Participations Ag | Novel microbiocides |
| TW201033201A (en) | 2009-02-19 | 2010-09-16 | Hoffmann La Roche | Isoxazole-isoxazole and isoxazole-isothiazole derivatives |
| ES2643403T3 (es) | 2011-12-28 | 2017-11-22 | Global Blood Therapeutics, Inc. | Compuestos de benzaldehído sustituidos y métodos para su uso en el aumento de la oxigenación tisular |
| WO2013102145A1 (en) | 2011-12-28 | 2013-07-04 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
| WO2014145040A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
| US20150057251A1 (en) | 2013-08-26 | 2015-02-26 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| SG11201507351PA (en) * | 2013-03-15 | 2015-10-29 | Global Blood Therapeutics Inc | Compounds and uses thereof for the modulation of hemoglobin |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9604999B2 (en) | 2013-03-15 | 2017-03-28 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9802900B2 (en) | 2013-03-15 | 2017-10-31 | Global Blood Therapeutics, Inc. | Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin |
| ES2890077T3 (es) | 2013-03-15 | 2022-01-17 | Global Blood Therapeutics Inc | Compuestos y usos de los mismos para la modulación de la hemoglobina |
| US20140271591A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Compositions and methods for the modulation of hemoglobin (s) |
| US20140274961A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| AU2014237340C1 (en) | 2013-03-15 | 2018-11-08 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US20160206604A1 (en) | 2013-08-26 | 2016-07-21 | Global Blood Therapeutics, Inc. | Formulations comprising wetting agents and compounds for the modulation of hemoglobin (s) |
| US20160207904A1 (en) | 2013-08-27 | 2016-07-21 | Global Blood Therapeutics, Inc. | Crystalline 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde ansolvate salts |
| US20150141465A1 (en) | 2013-11-18 | 2015-05-21 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| US9248199B2 (en) | 2014-01-29 | 2016-02-02 | Global Blood Therapeutics, Inc. | 1:1 adducts of sickle hemoglobin |
| SG10201911662YA (en) | 2014-02-07 | 2020-02-27 | Global Blood Therapeutics Inc | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
| MA41841A (fr) | 2015-03-30 | 2018-02-06 | Global Blood Therapeutics Inc | Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs |
| TW201731509A (zh) | 2015-12-04 | 2017-09-16 | 全球血液治療公司 | 針對２-羥基-６-（（２-（１-異丙基-１ｈ-吡唑-５-基）吡啶-３-基）甲氧基）-苯甲醛之劑量方案 |
| TWI752307B (zh) | 2016-05-12 | 2022-01-11 | 美商全球血液治療公司 | 新穎化合物及製造化合物之方法 |
| TW202332423A (zh) | 2016-10-12 | 2023-08-16 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
| LT3880654T (lt) * | 2018-11-19 | 2022-02-25 | Global Blood Therapeutics, Inc. | 2-formil-3-hidroksifeniloksimetilo junginiai, galintys moduliuoti hemoglobiną |
-
2019
- 2019-11-18 LT LTEPPCT/US2019/062054T patent/LT3880654T/lt unknown
- 2019-11-18 PL PL19818401T patent/PL3880654T3/pl unknown
- 2019-11-18 BR BR112021007044-3A patent/BR112021007044B1/pt active IP Right Grant
- 2019-11-18 ES ES19818401T patent/ES2908325T3/es active Active
- 2019-11-18 HU HUE19818401A patent/HUE057323T2/hu unknown
- 2019-11-18 EP EP21217304.1A patent/EP4046988A1/en active Pending
- 2019-11-18 US US16/687,474 patent/US10683285B2/en active Active
- 2019-11-18 SG SG11202104705RA patent/SG11202104705RA/en unknown
- 2019-11-18 CN CN201980088809.5A patent/CN113316568B/zh active Active
- 2019-11-18 MD MDE20210907T patent/MD3880654T2/ro unknown
- 2019-11-18 MA MA54231A patent/MA54231B1/fr unknown
- 2019-11-18 CA CA3120380A patent/CA3120380A1/en active Pending
- 2019-11-18 DK DK19818401.2T patent/DK3880654T3/da active
- 2019-11-18 CR CR20210335A patent/CR20210335A/es unknown
- 2019-11-18 PT PT198184012T patent/PT3880654T/pt unknown
- 2019-11-18 IL IL283128A patent/IL283128B1/en unknown
- 2019-11-18 JP JP2021527206A patent/JP7509772B2/ja active Active
- 2019-11-18 HR HRP20220295TT patent/HRP20220295T1/hr unknown
- 2019-11-18 EP EP19818401.2A patent/EP3880654B1/en active Active
- 2019-11-18 RS RS20220126A patent/RS62970B1/sr unknown
- 2019-11-18 SI SI201930191T patent/SI3880654T1/sl unknown
- 2019-11-18 TW TW108141848A patent/TWI841630B/zh active
- 2019-11-18 WO PCT/US2019/062054 patent/WO2020106642A1/en active Application Filing
- 2019-11-18 AU AU2019383960A patent/AU2019383960B2/en active Active
- 2019-11-18 MX MX2021005887A patent/MX2021005887A/es unknown
- 2019-11-18 KR KR1020217018851A patent/KR20210093990A/ko not_active Application Discontinuation
-
2020
- 2020-05-04 US US16/865,625 patent/US11548880B2/en active Active
-
2021
- 2021-05-17 SA SA521422031A patent/SA521422031B1/ar unknown
- 2021-06-18 CO CONC2021/0007993A patent/CO2021007993A2/es unknown
-
2022
- 2022-02-28 CY CY20221100163T patent/CY1125025T1/el unknown
- 2022-11-21 US US17/991,448 patent/US20230159507A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283128A (en) | 2-formyl-3-hydroxyphenyloxymethyl compounds capable of modulating hemoglobin | |
| IL271149A (en) | Compounds for modulating s1p1 activity and methods of using them | |
| EP3768854A4 (en) | HSD17B13 EXPRESSION MODULATORS | |
| GB201804514D0 (en) | Treatment of pyroptosis | |
| IL283672A (en) | trex1 modulators | |
| IL281492A (en) | Modulators of PNPLA3 expression | |
| IL283967A (en) | Modulators of hsd17b13 expression | |
| IL256055B (en) | Using h3k9me3 modulation to enhance cognitive function | |
| IL283408A (en) | Pyrazoles as modulators of hemoglobin | |
| GB201804515D0 (en) | Treatment of necroptosis | |
| EP3259256A4 (en) | COMPOUNDS AND METHODS FOR INDUCING BROWNING OF WHITE ADIPOSE TISSUE | |
| EP3302696A4 (en) | Patient specific frequency modulation adaption | |
| IL282731A (en) | Organogulfonic compounds | |
| ZA201907406B (en) | Trpv1 modulator compounds | |
| SG11202105136WA (en) | Application of chidamide | |
| EP3548620A4 (en) | MODULATION OF THE EXPRESSION OF LNC05 | |
| GB201918992D0 (en) | GPR52 modulator compounds | |
| GB201918974D0 (en) | Gpr52 modulator compounds | |
| GB201916298D0 (en) | GPR52 modulator compounds | |
| GB201821093D0 (en) | Treatment of hydrocarbons | |
| IL262623A (en) | tourniquet | |
| GB201710054D0 (en) | PBC compounds | |
| EP3446689A4 (en) | USE OF ISOTHIOCYANATE COMPOUNDS | |
| PT3377106T (pt) | Modulação da ciliogénese |